NASDAQ:VBIV VBI Vaccines (VBIV) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free VBIV Stock Alerts $0.57 +0.01 (+1.79%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.57▼$0.5950-Day Range$0.56▼$0.7152-Week Range$0.45▼$10.50Volume51,553 shsAverage Volume131,884 shsMarket Capitalization$13.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get VBI Vaccines alerts: Email Address VBI Vaccines MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.41% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.97Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.73 out of 5 starsMedical Sector586th out of 947 stocksPharmaceutical Preparations Industry273rd out of 435 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for VBI Vaccines. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.41% of the float of VBI Vaccines has been sold short.Short Interest Ratio / Days to CoverVBI Vaccines has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VBI Vaccines has recently decreased by 15.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVBI Vaccines does not currently pay a dividend.Dividend GrowthVBI Vaccines does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVBI Vaccines has received a 51.81% net impact score from Upright. VBI Vaccines seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for VBI Vaccines is -0.75. Previous Next 2.8 News and Social Media Coverage News SentimentVBI Vaccines has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for VBI Vaccines this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for VBIV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added VBI Vaccines to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VBI Vaccines insiders have not sold or bought any company stock.Percentage Held by Insiders10.35% of the stock of VBI Vaccines is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.08% of the stock of VBI Vaccines is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of VBI Vaccines is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VBI Vaccines is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVBI Vaccines has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyUrgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.Click here now to get what could be the most urgent, and most lucrative research, my team has ever r About VBI Vaccines Stock (NASDAQ:VBIV)VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.Read More VBIV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VBIV Stock News HeadlinesMarch 17, 2024 | americanbankingnews.comVBI Vaccines (NASDAQ:VBIV) Research Coverage Started at StockNews.comMarch 16, 2024 | americanbankingnews.comVBI Vaccines Inc. (NASDAQ:VBIV) Short Interest UpdateMarch 19, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. March 9, 2024 | americanbankingnews.comVBI Vaccines (NASDAQ:VBIV) Earns Sell Rating from Analysts at StockNews.comFebruary 15, 2024 | bizjournals.comNorth Carolina biotech inks $30M deal to expand its global pipelineFebruary 14, 2024 | msn.comVBI signs deal to sell manufacturing capabilities, certain assets with Brii BiosciencesFebruary 14, 2024 | finance.yahoo.comStrategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI VaccinesFebruary 14, 2024 | benzinga.comWhy Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving PremarketMarch 19, 2024 | Porter & Company (Ad)Urgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.February 14, 2024 | finance.yahoo.comVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesFebruary 14, 2024 | businesswire.comVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesFebruary 13, 2024 | markets.businessinsider.comBrii Biosciences To Buy VBI's IP Rights In BRII-179February 13, 2024 | prnewswire.comBrii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial SuppliesFebruary 7, 2024 | msn.comVBI Vaccines Secures Forbearance Agreement ExtensionsNovember 20, 2023 | finance.yahoo.comVBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual MeetingNovember 14, 2023 | msn.comVBI Vaccines Non-GAAP EPS of -$0.38, revenue of $6.62M misses by $6.63MNovember 14, 2023 | finance.yahoo.comVBI Vaccines Reports Third Quarter 2023 Financial ResultsOctober 26, 2023 | finance.yahoo.comVBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine ProgramSeptember 30, 2023 | yahoo.comThese Are the Side Effects You Can Expect From the New COVID Vaccine, According to ImmunologistsSeptember 27, 2023 | msn.comVBI Vaccines’ pan-coronavirus vaccine candidate produced broad protection against COVID variants of concernSeptember 27, 2023 | markets.businessinsider.comVBI Vaccines To Advance Coronavirus Vaccine ProgramSeptember 27, 2023 | finance.yahoo.comVBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of ConcernSeptember 7, 2023 | finance.yahoo.comVBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBMSeptember 6, 2023 | msn.comVBI Vaccines gains after Phase 2 data for Hep B candidateSeptember 6, 2023 | finance.yahoo.comVBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis BAugust 14, 2023 | seekingalpha.comVBI Vaccines GAAP EPS of -$5.05 misses by $2.89, revenue of $0.74M misses by $0.19MAugust 14, 2023 | finance.yahoo.comVBI Vaccines Reports Second Quarter 2023 Financial ResultsSee More Headlines Receive VBIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2023Today3/18/2024Next Earnings (Estimated)3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VBIV CUSIPN/A CIK764195 Webwww.vbivaccines.com Phone(617) 830-3031FaxN/AEmployees190Year Founded2001Profitability EPS (Most Recent Fiscal Year)($11.6824) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,300,000.00 Net Margins-1,403.15% Pretax Margin-1,403.15% Return on Equity-199.61% Return on Assets-58.20% Debt Debt-to-Equity RatioN/A Current Ratio0.65 Quick Ratio0.55 Sales & Book Value Annual Sales$1.08 million Price / Sales12.51 Cash FlowN/A Price / Cash FlowN/A Book Value$7.46 per share Price / Book0.08Miscellaneous Outstanding Shares23,690,000Free Float21,236,000Market Cap$13.51 million OptionableOptionable Beta1.92 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Jeffery R. Baxter FCMA (Age 63)President, CEO & Director Comp: $908.06kDr. David Evander Anderson (Age 54)Chief Scientific Officer Comp: $534.25kDr. Francisco Diaz-Mitoma FRCPC (Age 69)M.D., Ph.D., Chief Medical Officer Comp: $544.52kMs. Nell Beattie (Age 36)CFO, Head of Corporate Development & Director Nicole AndersonDirector of Corporate Communications & Investor RelationsMs. Athena Kartsaklis (Age 59)Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer Mr. Avi Mazaltov (Age 62)Global Head of Manufacturing & GM of SciVac Mr. Misha NossovSenior VP of Global Commercial Supply Strategy & Head of EuropeMr. T. Adam Buckley (Age 48)Senior Vice President of Business Development Mr. John Robert Dillman (Age 56)Chief Commercial Officer More ExecutivesKey CompetitorsEdesa BiotechNASDAQ:EDSANanoViricidesNYSE:NNVCCocrystal PharmaNASDAQ:COCPElevai LabsNASDAQ:ELABEterna TherapeuticsNASDAQ:ERNAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 119,914 shares on 3/11/2024Ownership: 0.779%Vanguard Group Inc.Bought 119,914 shares on 2/15/2024Ownership: 0.779%Citadel Advisors LLCSold 1,000 shares on 2/15/2024Ownership: 0.000%Steven GillisBought 609,090 shares on 7/10/2023Total: $1.00 M ($1.65/share)Perceptive Advisors LlcSold 212,578 sharesTotal: $467,671.60 ($2.20/share)View All Insider TransactionsView All Institutional Transactions VBIV Stock Analysis - Frequently Asked Questions How have VBIV shares performed in 2024? VBI Vaccines' stock was trading at $0.5875 at the start of the year. Since then, VBIV shares have decreased by 3.0% and is now trading at $0.5701. View the best growth stocks for 2024 here. Are investors shorting VBI Vaccines? VBI Vaccines saw a decrease in short interest during the month of February. As of February 29th, there was short interest totaling 313,500 shares, a decrease of 15.7% from the February 14th total of 371,700 shares. Based on an average daily trading volume, of 130,200 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.4% of the shares of the company are short sold. View VBI Vaccines' Short Interest. When is VBI Vaccines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024. View our VBIV earnings forecast. How were VBI Vaccines' earnings last quarter? VBI Vaccines Inc. (NASDAQ:VBIV) posted its quarterly earnings data on Monday, March, 13th. The biopharmaceutical company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.40) by $0.20. The biopharmaceutical company earned $0.29 million during the quarter, compared to the consensus estimate of $1.98 million. VBI Vaccines had a negative trailing twelve-month return on equity of 199.61% and a negative net margin of 1,403.15%. When did VBI Vaccines' stock split? Shares of VBI Vaccines reverse split on Wednesday, April 12th 2023. The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of VBI Vaccines own? Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie (). Who are VBI Vaccines' major shareholders? VBI Vaccines' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.78%), Vanguard Group Inc. (0.78%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc and Steven Gillis. View institutional ownership trends. How do I buy shares of VBI Vaccines? Shares of VBIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VBIV) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VBI Vaccines Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.